FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL OMB Number: Estimated average burden

0.5

hours per response:

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Cox John					2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [BIIB]									(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify				
	(FI N IDEC INC STON POST	<u>.</u>	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 02/09/2012										below) below) VP Pharmaceutical Oper & Tec			` <i>`</i>	
(Street) WESTO (City)	N M	[A	02493 (Zip)		_ 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tab	le I - No	n-Deriv	ative/	Sec	uriti	ies Ac	quired	, Dis	sposed o	of, or I	3ene	ficiall	y Owned	k			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4				Benefici Owned	es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) (D)	or P	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common	Stock			02/09	/2012				М		4,692	! <i>I</i>	A	\$0	14,28	80.0295		D	
Common	Stock			02/09	/2012				F		1,504	I) 1	117.7	78 12,776.0295 D			D	
		Т	able II -								osed of converti				Owned				
Security or Exercise (Month/Day/Year) if a				n Date,	4. Transaction Code (Instr. 8)		n of E		6. Date Exercisa Expiration Date (Month/Day/Yea		е	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)) ,	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Ow Fo Dir or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	or Nu of	nount imber iares					
Restricted Stock Unit	\$0 ⁽²⁾	02/09/2012			M			4,692	(1)		02/09/2015	Commo		,692	\$0	14,074	1	D	

Explanation of Responses:

2. There is no conversion or exercise price for this stock unit.

Aras Lapinskas, Attorney in Fact for John Cox

02/13/2012

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).